Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company specializing in AI-Immunology™ powered vaccines, has announced it will provide a business update and report second quarter 2024 financial results on August 14, 2024, before the Nasdaq-CM opens. The company's Executive Management will host a conference call and webcast at 14:30 CEST/08:30 EDT on the same day to present the update and results, as well as take questions. This event is free and open to the public. Interested parties can register in advance to receive dial-in details and a unique pin code for the conference call. A webcast link is also provided, and a recording will be available on Evaxion's website shortly after the event.
Evaxion Biotech A/S (NASDAQ: EVAX), una compagnia TechBio in fase clinica specializzata in vaccini potenziati da AI-Immunology™, ha annunciato che fornirà un aggiornamento aziendale e riporterà i risultati finanziari del secondo trimestre 2024 il 14 agosto 2024, prima dell'apertura del Nasdaq-CM. Il Management Esecutivo della società ospiterà una conference call e webcast alle 14:30 CEST/08:30 EDT nello stesso giorno per presentare l'aggiornamento e i risultati, oltre a rispondere a domande. Questo evento è gratuito e aperto al pubblico. Le parti interessate possono registrarsi in anticipo per ricevere i dettagli per la chiamata e un codice pin unico per la conferenza. È fornito anche un link per il webcast, e una registrazione sarà disponibile sul sito web di Evaxion subito dopo l'evento.
Evaxion Biotech A/S (NASDAQ: EVAX), una empresa TechBio en etapa clínica especializada en vacunas impulsadas por AI-Immunology™, ha anunciado que proporcionará un informe empresarial y reportará resultados financieros del segundo trimestre de 2024 el 14 de agosto de 2024, antes de la apertura de Nasdaq-CM. La Dirección Ejecutiva de la empresa organizará una videoconferencia y webcast a las 14:30 CEST/08:30 EDT el mismo día para presentar la actualización y los resultados, así como para responder preguntas. Este evento es gratuito y abierto al público. Las partes interesadas pueden registrarse con antelación para recibir detalles de acceso y un código pin único para la conferencia. También se proporcionará un enlace de webcast, y una grabación estará disponible en el sitio web de Evaxion poco después del evento.
Evaxion Biotech A/S (NASDAQ: EVAX)는 AI-Immunology™ 기반 백신을 전문으로 하는 임상 단계의 TechBio 회사로, 2024년 2분기 재무 결과를 발표하고 사업 업데이트를 제공할 것이라고 발표했다. 이 발표는 2024년 8월 14일, Nasdaq-CM이 열리기 전에 이루어진다. 회사의 경영진은 같은 날 14:30 CEST/08:30 EDT에 컨퍼런스 콜 및 웹캐스트를 주최하여 업데이트와 결과를 발표하고 질문에 답변할 예정이다. 이 행사는 무료이며 대중에게 개방된다. 관심 있는 당사자는 사전 등록을 통해 전화 회의에 대한 다이얼인 세부정보와 고유한 핀 코드를 받을 수 있다. 웹캐스트 링크도 제공되며, 이벤트 직후 Evaxion의 웹사이트에 녹화된 내용이 업로드될 예정이다.
Evaxion Biotech A/S (NASDAQ: EVAX), une entreprise TechBio en phase clinique spécialisée dans les vaccins alimentés par AI-Immunology™, a annoncé qu'elle fournira une mise à jour commerciale et un rapport sur les résultats financiers du deuxième trimestre 2024 le 14 août 2024, avant l'ouverture de Nasdaq-CM. La direction exécutive de l'entreprise animera une conférence téléphonique et un webcast à 14h30 CEST/08h30 EDT le même jour pour présenter la mise à jour et les résultats, ainsi que répondre aux questions. Cet événement est gratuit et ouvert au public. Les parties intéressées peuvent s'inscrire à l'avance pour recevoir les détails de connexion et un code PIN unique pour la conférence téléphonique. Un lien de webcast est également fourni, et un enregistrement sera disponible sur le site Web d'Evaxion peu après l'événement.
Evaxion Biotech A/S (NASDAQ: EVAX), ein klinisches TechBio-Unternehmen, das sich auf von AI-Immunologie™ unterstützte Impfstoffe spezialisiert hat, hat angekündigt, ein geschäftliches Update zu geben und die finanziellen Ergebnisse des zweiten Quartals 2024 zu berichten am 14. August 2024, bevor die Nasdaq-CM öffnet. Das Führungsteam des Unternehmens wird am selben Tag um 14:30 CEST/08:30 EDT eine Telefonkonferenz und einen Webcast veranstalten, um das Update und die Ergebnisse zu präsentieren sowie Fragen zu beantworten. Diese Veranstaltung ist kostenlos und öffentlich zugänglich. Interessierte können sich im Voraus registrieren, um Anmeldedaten und einen einzigartigen PIN-Code für die Telefonkonferenz zu erhalten. Ein Webcast-Link wird ebenfalls bereitgestellt und eine Aufzeichnung wird kurz nach der Veranstaltung auf der Website von Evaxion verfügbar sein.
- None.
- None.
COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM.
Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CEST/08:30 EDT presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.
To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique pin code. The call can be accessed 15 minutes prior to the start of the live event.
To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.
Contact Information
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion-biotech.com
Source: Evaxion Biotech
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
Forward-Looking Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide ongoing COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia and the Middle East; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
When will Evaxion Biotech (EVAX) release its Q2 2024 financial results?
What time is Evaxion Biotech's (EVAX) Q2 2024 earnings call scheduled for?
How can I participate in Evaxion Biotech's (EVAX) Q2 2024 earnings call?
Will Evaxion Biotech (EVAX) provide a business update along with its Q2 2024 results?
